TY - JOUR
T1 - Clinical Implications of Kratom (Mitragyna speciosa) Use
T2 - a Literature Review
AU - Prevete, Elisabeth
AU - Kuypers, Kim Paula Colette
AU - Theunissen, Eef Lien
AU - Esposito, Gianluca
AU - Ramaekers, Johannes Gerardus
AU - Pasquini, Massimo
AU - Corazza, Ornella
PY - 2023/6/1
Y1 - 2023/6/1
N2 - Purpose of Review: This work aims to provide an up-to-date review of the preclinical and clinical scientific literature on the therapeutic value of kratom to better understand the underlying mechanisms related to its use and inform future therapeutic applications. Recent Findings: A growing number of studies, mainly of cross-sectional nature, describe the widespread use of kratom by individuals to self-treat pain, psychiatric symptoms, and substance use disorders (SUD) outside a controlled clinical setting. Preclinical evidence suggests kratom is effective as an analgesic agent and might decrease the self-administration of other drugs. A randomized controlled trial has further supported kratom’s therapeutic value as an analgesic. Investigations in nonclinical samples of long-term kratom users also indicate its therapeutic benefit in managing SUD symptoms (e.g., craving) and long-term or acute symptoms (e.g., withdrawal) for alcohol, opioids, and other illicit drugs. However, episodes of kratom-related intoxications have also been reported, often due to the adulteration and the contamination of kratom products mainly sold online or mixed toxicities when consumed outside clinical and traditional settings. Summary: Evidence on the clinical implications of kratom use is still limited and uncertain, with kratom research constantly evolving. Therefore, further randomized trials are needed.
AB - Purpose of Review: This work aims to provide an up-to-date review of the preclinical and clinical scientific literature on the therapeutic value of kratom to better understand the underlying mechanisms related to its use and inform future therapeutic applications. Recent Findings: A growing number of studies, mainly of cross-sectional nature, describe the widespread use of kratom by individuals to self-treat pain, psychiatric symptoms, and substance use disorders (SUD) outside a controlled clinical setting. Preclinical evidence suggests kratom is effective as an analgesic agent and might decrease the self-administration of other drugs. A randomized controlled trial has further supported kratom’s therapeutic value as an analgesic. Investigations in nonclinical samples of long-term kratom users also indicate its therapeutic benefit in managing SUD symptoms (e.g., craving) and long-term or acute symptoms (e.g., withdrawal) for alcohol, opioids, and other illicit drugs. However, episodes of kratom-related intoxications have also been reported, often due to the adulteration and the contamination of kratom products mainly sold online or mixed toxicities when consumed outside clinical and traditional settings. Summary: Evidence on the clinical implications of kratom use is still limited and uncertain, with kratom research constantly evolving. Therefore, further randomized trials are needed.
KW - Kratom
KW - Mitragynine
KW - Mitragyna speciosa
KW - Clinical implications
KW - Therapeutic use
KW - Adverse effects
KW - PREVALENCE
KW - EXTRACT
KW - DEATH
U2 - 10.1007/s40429-023-00478-3
DO - 10.1007/s40429-023-00478-3
M3 - (Systematic) Review article
C2 - 37266188
SN - 2196-2952
VL - 10
SP - 317
EP - 334
JO - Current Addiction Reports
JF - Current Addiction Reports
IS - 2
ER -